European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/23/2026

1. GOOGL
2. TSLA
3. TXN
4. NOW
5. GOOG
6. CSX
7. IBM
8. KNX
9. AMD
10. INTC

Go back to European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
(NASDAQ: RVMD) Delayed: 188.68 +5.65 (3.09%)
Previous Close $183.03    52 Week High $ 
Open $182.61    52 Week Low $ 
Day High $193.53    P/E N/A 
Day Low $180.00    EPS $ 
Volume 1,391,486